Oxidative stress reflected by increased F2-isoprostanes is associated with increasing urinary 11-dehydro thromboxane B2levels in patients with coronary artery disease.
Baylor University Medical Center, Dallas, TX, United States; Baylor Heart and Vascular Institute, Dallas, TX, United States; Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, TX, United States; The Heart Hospital Baylor Plano, Plano, TX, United States; Texas A&M Health Science Center College of Medicine, Dallas Campus, Dallas, TX, United States. Electronic address: peteramccullough@gmail.com.
Peter A
PA
McCullough
Baylor Heart and Vascular Institute, Dallas, TX, United States; Texas A&M Health Science Center College of Medicine, Dallas Campus, Dallas, TX, United States; Baylor Research Institute, Dallas, TX, United States. Electronic address: Anupama.Vasudevan@BSWHealth.org.
Anupama
A
Vasudevan
Corgenix Inc., Broomfield, CO, United States. Electronic address: LLopez@corgenix.com.
Luis R
LR
Lopez
Baylor Research Institute, Dallas, TX, United States; Institute of Metabolic Disease, Dallas, TX, United States. Electronic address: Caren.Swift@BSWHealth.org.
Caren
C
Swift
Baylor Research Institute, Dallas, TX, United States; Institute of Metabolic Disease, Dallas, TX, United States. Electronic address: mpeters@wakehealth.edu.
Margarita
M
Peterson
Baylor Research Institute, Dallas, TX, United States; Institute of Metabolic Disease, Dallas, TX, United States. Electronic address: Jeanna.bennettfirmin@bswhealth.org.
Jeanna
J
Bennett-Firmin
Baylor Research Institute, Dallas, TX, United States; Institute of Metabolic Disease, Dallas, TX, United States. Electronic address: Raphael.Schiffmann@BSWHealth.org.
Raphael
R
Schiffmann
Baylor Research Institute, Dallas, TX, United States; Institute of Metabolic Disease, Dallas, TX, United States. Electronic address: Teodoro.Bottiglieri@BSWHealth.org.
Teodoro
T
Bottiglieri
D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000378:metabolism* / Q000652:urine*; D003430:Cross-Sectional Studies; D051545:Cyclooxygenase 1 / Q000378:metabolism; D015237:Dinoprost / Q000031:analogs & derivatives / Q000378:metabolism / Q000652:urine; D028441:F2-Isoprostanes / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013929:Thromboxane B2 / Q000031:analogs & derivatives* / Q000378:metabolism / Q000652:urine
D028441:F2-Isoprostanes; D010975:Platelet Aggregation Inhibitors; C075750:8-epi-prostaglandin F2alpha; D013929:Thromboxane B2; C049235:11-dehydro-thromboxane B2; D015237:Dinoprost; D051545:Cyclooxygenase 1; C496511:PTGS1 protein, human; D001241:Aspirin